Metrics as of 10/16/2026, 03:14 PM (Berlin time), refresh in progress.
Vericel Stock
Vericel Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dominick C. Colangelo
- Employees
- 398
- Market cap
- $2.1 B
- IPO
- 04/02/1997
- Web
- vcel.com
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. The company's primary therapeutic areas are sports medicine and critical burn care across the United States. Its…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Vericel stock: price history
1D
+1.9%
1W
+2.4%
1M
+3.3%
6M
+21.5%
YTD
+13.9%
1Y
+22.1%
2Y
-2.2%
5Y
-19.2%
10Y
+1,588.1%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~0% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 15/10/26. Not a buy or sell signal.Beta
What does this mean?
Double bottom
BullishThe price bounced off a similar low twice, with a rally in between. This W-shaped pattern is a classic reversal signal from a downtrend into an uptrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Vericel
Analyst assessment of Vericel
PRICE TARGET LOW
US$52.00
CONSENSUS
US$60.67
MEDIAN
US$60.00
PRICE TARGET HIGH
US$70.00
0
STRONG BUY
9
BUY
5
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 14/10/2026
Vericel stock metrics
P/E
85.46
P/B
5.65
EV/EBITDA
53.28
RETURN ON EQUITY
0.6%
NET MARGIN
2.8%
DEBT/EQUITY
0.25
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
98.8%
FLOAT SHARES
50,576,773
AVG. DAILY VOLUME (30D)
521,724
Insider transactions (SEC)
MCLAUGHLIN KEVIN F
MCLAUGHLIN KEVIN F
Halpin Michael
Halpin Michael
SIEGAL JONATHAN
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Vericel stock
What does Vericel do?
Vericel Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dominick C. Colangelo, the company employs around 398 people.
The IPO was on 04/02/1997; the stock trades on NASDAQ under the ticker VCEL.
What do analysts say about Vericel stock?
14 analysts rate the stock, the consensus is Buy (as of 14/10/2026).
The average price target is US$60.67, ranging from US$52.00 to US$70.00, with a median of US$60.00.
This is an external assessment, not a statement by Market Jury.
When does Vericel report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 0% stronger than usual.
Does Vericel pay a dividend?
No, Vericel currently does not pay a dividend.
Which stocks are comparable to Vericel?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Vericel stock analyzed?
Clicking "Analyze stock" lets five strategies assess Vericel against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.